Bellevue Group
$4.8B 13F equity value
172 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Bellevue Group covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| AMGN | AMGEN INC | 851,550 | $308M | 6.5% |
| VRTX | VERTEX PHARMACEUTICALS INC | 578,634 | $287M | 6.0% |
| ARGX | ARGENX SE | 301,000 | $279M | 5.9% |
| GILD | GILEAD SCIENCES INC | 2,158,772 | $273M | 5.7% |
| RVMD | REVOLUTION MEDICINES INC | 1,048,014 | $196M | 4.1% |
| ORKA | ORUKA THERAPEUTICS INC | 1,657,190 | $158M | 3.3% |
| INSM | INSMED INC | 1,393,418 | $149M | 3.1% |
| SRRK | SCHOLAR ROCK HLDG CORP | 2,449,547 | $135M | 2.8% |
| NUVL | NUVALENT INC | 1,053,268 | $130M | 2.7% |
| VRDN | VIRIDIAN THERAPEUTICS INC | 6,731,909 | $124M | 2.6% |
Track Bellevue Group's 13F portfolio: $4.8B in reported holdings, 172 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}